Fanconi anemia (FA) is a rare genomic instability disorder characterized by progressive bone marrow failure and predisposition to cancer. FAassociated gene products are involved in the repair of DNA interstrand crosslinks (ICLs). Fifteen FA-associated genes have been identified, but the genetic basis in some individuals still remains unresolved. Here, we used whole-exome and Sanger sequencing on DNA of unclassified FA individuals and discovered biallelic germline mutations in ERCC4 (XPF), a structure-specific nuclease-encoding gene previously connected to xeroderma pigmentosum and segmental XFE progeroid syndrome. Genetic reversion and wild-type ERCC4 cDNA complemented the phenotype of the FA cell lines, providing genetic evidence that mutations in ERCC4 cause this FA subtype. Further biochemical and functional analysis demonstrated that the identified FA-causing ERCC4 mutations strongly disrupt the function of XPF in DNA ICL repair without severely compromising nucleotide excision repair. Our data show that depending on the type of ERCC4 mutation and the resulting balance between both DNA repair activities, individuals present with one of the three clinically distinct disorders, highlighting the multifunctional nature of the XPF endonuclease in genome stability and human disease. (MIM 227650, 300514, 227645, 605724, 227646, 600901, 603467, 614082, 609053, 609054, 614083, 614087, 610832, 613390, and 613951, respectively). Studies to unravel the genetic basis of this rare disorder uncovered a genome-maintenance pathway that protects dividing cells against replication-blocking DNA lesions. To identify additional FA-associated genes, we used the SOLiD 4 platform for whole-exome sequencing on peripheral-blood DNA from a Spanish FA individual (FA104) who was previously excluded from all known FA complementation groups (this study was approved by the Institutional Committee on Ethical Research in Human Samples, and proper informed consent was obtained). FA104 was born to unrelated parents and was diagnosed neonatally with a malformative syndrome suggestive of FA, the symptoms of which included bilateral absent thumbs, microsomy, esophageal atresia, a ventrally translocated anus, and dysplastic and low-set ears. She did not show any dermatological abnormality such as skin hyperpigmentation, photosensitivity,
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Fanconi anemia (FA) is a rare genomic instability disorder characterized by progressive bone marrow failure and predisposition to cancer. FAassociated gene products are involved in the repair of DNA interstrand crosslinks (ICLs). Fifteen FA-associated genes have been identified, but the genetic basis in some individuals still remains unresolved. Here, we used whole-exome and Sanger sequencing on DNA of unclassified FA individuals and discovered biallelic germline mutations in ERCC4 (XPF), a structure-specific nuclease-encoding gene previously connected to xeroderma pigmentosum and segmental XFE progeroid syndrome. Genetic reversion and wild-type ERCC4 cDNA complemented the phenotype of the FA cell lines, providing genetic evidence that mutations in ERCC4 cause this FA subtype. Further biochemical and functional analysis demonstrated that the identified FA-causing ERCC4 mutations strongly disrupt the function of XPF in DNA ICL repair without severely compromising nucleotide excision repair. Our data show that depending on the type of ERCC4 mutation and the resulting balance between both DNA repair activities, individuals present with one of the three clinically distinct disorders, highlighting the multifunctional nature of the XPF endonuclease in genome stability and human disease.
Fanconi anemia (FA) is characterized by bone marrow failure (BMF), congenital malformations, hypersensitivity to DNA interstrand crosslink (ICL)-inducing agents, chromosome fragility, and a high susceptibility to cancer. Since the discovery of the first FA-associated gene 20 years ago, all together, 15 genes associated with FA have been identified; these include FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, FANCE, FANCF, FANCG (XRCC9), FANCI, FANCJ (BRIP1), FANCL (PHF9), FANCM, FANCN (PALB2), FANCO (RAD51C), and FANCP (SLX4) 1,2 (MIM 227650, 300514, 227645, 605724, 227646, 600901, 603467, 614082, 609053, 609054, 614083, 614087, 610832, 613390, and 613951, respectively). Studies to unravel the genetic basis of this rare disorder uncovered a genome-maintenance pathway that protects dividing cells against replication-blocking DNA lesions. To identify additional FA-associated genes, we used the SOLiD 4 platform for whole-exome sequencing on peripheral-blood DNA from a Spanish FA individual (FA104) who was previously excluded from all known FA complementation groups (this study was approved by the Institutional Committee on Ethical Research in Human Samples, and proper informed consent was obtained). FA104 was born to unrelated parents and was diagnosed neonatally with a malformative syndrome suggestive of FA, the symptoms of which included bilateral absent thumbs, microsomy, esophageal atresia, a ventrally translocated anus, and dysplastic and low-set ears. She did not show any dermatological abnormality such as skin hyperpigmentation, photosensitivity,
Mutations in ERCC4 cause Fanconi anemia
sunlight-induced scarring, or atrophy. FA104 developed BMF at the age of 2 years and died as a result of a hemorrhagic shock after bone marrow transplantation at the age of 4 years. A positive chromosome-breakage test unambiguously confirmed the FA diagnosis: 92% of the cells showed on average 4.4 diepoxybutane (DEB)-induced breaks. Lymphoblasts from this individual were hypersensitive to mitomycin-C (MMC) and melphalan but were insensitive to the topoisomerase I inhibitor camptothecin and the PARP inhibitor KU58948 (data not shown) and showed normal FANCD2 monoubiquitination and RAD51 focus formation 3 . This suggests a defect downstream within the FA pathway, which does not involve homologous recombination. On the basis of a recessive mode of inheritance, exome sequencing identified 17 candidate disease genes for FA104 (Supplementary Table 1) ; of these, ERCC4 (MIM 133520; also known as XPF) immediately caught our attention given the involvement of the XPF-ERCC1-structure-specific nuclease in ICL repair 4 . Both ERCC4 mutations were predicted to be pathogenic: a 5 bp deletion in exon 8 (c.1484_1488delCTCAA) was predicted to lead to a frameshift and a premature stop codon (p.Thr495Asnfs*6), and a missense mutation in exon 11 (c.2065C>A [p.Arg689Ser]; RefSeq accession numbers NG_011442.1, NM_005236.2, and NP_005227.1) was predicted to change a highly conserved arginine within the nuclease active site of XPF. Sanger sequencing on blood DNA confirmed these mutations (Fig. 1A) and their correct segregation (data not shown). In MMCresistant FA104 lymphoblasts (FA104R) obtained after long-term exposure to a low dose of MMC, we detected a mutation that restored the ERCC4 reading frame (Supplementary Fig. 1A ), supporting the notion that MMC sensitivity is due to ERCC4 mutations. Consistently, XPF levels were reduced in FA104 lymphoblasts but were normalized in the reverted FA104R lymphoblasts ( Supplementary  Fig. 1B ). Immunoblotting did not detect a truncated XPF, indicating that only the p.Arg689Ser altered XPF was present in the FA104 cell line.
Sanger sequencing on 18 unclassified FA individuals from Germany revealed biallelic ERCC4 mutations in another individual (1333). Individual 1333 was born in 2002 and was unambiguously diagnosed with FA at the age of 5 years as a result of multiple FA-related features, such as perinatal growth retardation, short stature, pronounced microcephaly, café-au-lait spots, an ostium-primum defect, biliary atresia with fibrosis of the liver, BMF, and a positive chromosome-fragility test (0.2, 6.7, and 9.4 breaks per cell at 0, 50, and 100 ng/ml MMC, respectively). Individual 1333 is redheaded and has pale skin color, but no spontaneous or UV-light-induced skin lesions were reported at the age of 10 years. Similar to those of FA104, lymphoblasts from individual 1333 were normal with regard to FANCD2 monoubiquitination and RAD51 focus formation and were sensitive to MMC and melphalan but insensitive to the topoisomerase I inhibitor camptothecin and to the PARP inhibitor KU58948 (data not shown). Individual 1333 carries a 28 bp duplication in exon 11 of the maternal , and an unrelated ERCC4 mutation carrier (Het) were used as controls. XPF levels are expressed as a ratio relative to the loading control (RAD50). (D) Genetic complementation of MMC sensitivity in FA104 lymphoblasts by wild-type XPF, but not by p.Arg689Ser altered XPF. Site-directed mutagenesis was used for introducing point mutations into the pWPXL-XPF hemagglutinin (HA)-tagged plasmid with the QuickChange method (Stratagene) as described 5 . Lentiviral supernatant production and transduction were done as previously described 6 , and cells were grown for 10 days in the presence of MMC. Fig. 1B) . Immunoblot analysis showed that a missense altered XPF and a truncated 90-95 kDa XPF are present at very low levels (Fig. 1C) . As expected, the truncated XPF was undetectable with an antibody against the C-terminal HhH 2 domain of XPF (amino acids 866-916, data not shown). Interestingly, the truncated XPF was absent in a MMC resistant lymphoblastoid cell line (1333R) generated by long-term exposure to MMC, and near-normal XPF levels were detected in this reverted cell line ( Supplementary Fig. 1C ). PCR amplification and sequence analysis revealed that the 28 bp duplication had disappeared in 1333R (Supplementary Fig. 1D ) and had thus restored the wild-type sequence. Both the inherited duplication and the somatic reversion might have been triggered by an inverted 5 bp repeat flanking the region.
Genetic complementation of MMC sensitivity in lymphoblasts from both FA individuals was achieved by lentiviral transduction of wild-type ERCC4 cDNA ( Fig. 1D and 1E ). In addition, we expressed wild-type and mutant human ERCC4 cDNAs in embryonic fibroblasts (MEFs) from Ercc4 (Xpf)-null mice. We found that ectopic expression of ERCC4 mutants encoding p.Leu230Pro and p.Arg689Ser did not complement MMC sensitivity of these MEFs (Fig. 1F) , providing additional evidence that the ERCC4 missense mutations found in both FA individuals inactivate XPF. The genetic and functional data show that mutations in ERCC4 cause FA in two unrelated nonconsanguineous individuals. Because mutations in ERCC4 cause an additional FA subtype (FA-Q), we propose FANCQ as an alias for ERCC4.
ERCC4 mutations have been linked to the skin-photosensitive and nucleotide excision repair (NER)-deficient disorders xeroderma pigmentosum (XP [MIM 278700, 610651, 278720, 278730, 278740, 278760, 278780, and 278750]) 8 and XFE progeroid syndrome (MIM 610965) 9 , and we therefore tried to understand why the identified ERCC4 variants specifically lead to FA. We hypothesized that these mutants cause an FA phenotype because of a strong deficiency in ICL repair but have sufficient NER activity to prevent clinically relevant skin photosensitivity and other NER-related features. Compared to an XP complementation group C (XP-C) lymphoblast line, FA104 lymphoblasts were indeed not sensitive to UVC light ( cell lines, we studied skin fibroblasts from individual 1333 (FA104 fibroblasts were not available) and found that the UV-light sensitivity in FA individual 1333 was milder than that in XP complementation group F (XP-F) individual XP2YO (Fig.  2B) . In addition, the FA-specific XPF alterations p.Leu230Pro and p.Arg689Ser rescued 100% of the UVC sensitivity of XP2YO fibroblasts (Supplementary Fig. 2A ) and approximately 80% of the UVC-light sensitivity of Ercc4-null MEFs ( Supplementary Fig. 2B ) but were both unable to complement MMC sensitivity (Fig. 1F) . Furthermore, XFE and 1333 fibroblasts responded typically like FA cells upon MMC-induced survival (Fig. 2C) , DEB-induced chromosome breakage (Fig.  2D) , and MMC-induced G2-phase arrest (Fig. 2E) , whereas XP-F cells showed milder MMC sensitivity and lacked DEB-induced chromosome fragility and MMCinduced cell-cycle arrest ( Fig. 2C-2E) . Previous experiments in Chinese hamster ovary cells also demonstrated that the XFE-specific p.Arg153Pro altered XPF does not rescue MMC or UV-light sensitivity
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. Therefore, we conclude that XP, XFE, and FA cells with ERCC4 mutations clearly have a distinct response to UV light and MMC (Supplementary Table 2) .
To further investigate the extent of NER deficiency in the FA-affected individuals, we measured UV-light-induced unscheduled DNA synthesis (UDS) in primary skin fibroblasts from individual 1333 and from an XP-F individual (XP42RO) with mild clinical UV-light sensitivity and found 24 ± 4% and 21 ± 3% residual UDS activity, respectively (Fig. 3A) . We also determined UDS in Ercc4-null MEFs expressing the FA-specific XPF alterations p.Leu230Pro or p.Arg689Ser. The levels of UDS activity were 39.7% and 48.4% of the normal mean for p.Leu230Pro and p.Arg689Ser altered XPF, respectively (Fig. 3B) , enough to complement 80% of UVC-light sensitivity of these MEFs (Supplementary Fig. 2B ). In XPF-deficient human XP2YO fibroblasts, p.Leu230Pro and p.Arg689Ser altered XPF rather efficiently corrected the defective removal of 6-4 photoproducts (PPs) at sites of local UV damage (Fig. 3C) . In contrast, XP2YO cells expressing the ERCC4 mutant with the 28 bp duplication were completely deficient in NER activity, as predicted from the disruption of the ERCC1-and DNA-binding domain of this truncated protein. The studies presented in Fig. 2 and 3 demonstrate that FA cells with ERCC4 mutations are fully deficient in ICL repair but retain significant levels of NER activity.
Cell lines from XP-F individuals show a characteristic failure of the altered XPF to properly translocate to the nucleus through aggregation of the protein in the cytoplasm
. This feature is evident for XP-causing mutations and accentuated in cells from the individual with XFE syndrome. However, FA-causing XPF missense altered proteins can actually translocate to the nucleus, where they are recruited to sites of active NER (Supplementary Fig. 3A and 3B ) and can interact with SLX4 and ERCC1 (Supplementary Fig. 3C and 3D) . These results might be functionally important, given that a recent article reports that SLX4 interaction with XPF is crucial for ICL repair and that SLX4-knockout mice phenocopy FA 13 . Using Xenopus extracts, J.C. Walter's group reported that the FA upstream pathway genes are required to regulate a nuclease that makes DNA incisions near the ICL
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Given that FA-specific altered XPF proteins can reach the site of damage, we then investigated their ability to cleave DNA. For this aim, the p.Arg689Ser altered XPF was purified as a heterodimer with ERCC1 as previously described 5 . Subsequently, NER reactions were performed with the purified altered protein, extracts from XPFdeficient XP2YO cells, and a plasmid containing an NER substrate (1,3-cisplatin intrastrand crosslink) 15 . Consistent with the functional data above, the purified heterodimer composed of ERCC1 and p.Arg689Ser XPF is proficient in the excision step of NER similarly to wild-type XPF, given that it restored the ability to cleave and remove the site-specific intrastrand crosslink from the plasmid in XP2YO cell extracts (Fig. 4A) . Nevertheless, the excision reaction is not perfect given that the excised fragments are, on average, 1 nucleotide longer than expected from a normal reaction with wild-type-XPF-ERCC1 dimer (Fig. 4A, lane 4) . We also performed in vitro nuclease activity assays with purified ERCC1-p.Arg689Ser-XPF and ERCC1-p. Arg689Ala-XPF on a stem-loop model DNA substrate. Unlike wild-type XPF and altered XPF proteins causing XP (p.Arg799Trp) or XFE progeroid syndrome (p.Arg153Pro) 11 , p.Arg689Ser XPF is unable to cleave such a substrate (Fig. 4B) , indicating that the nuclease-type activity of p.Arg689Ser XPF is grossly abnormal. Unfortunately, we could not perform these biochemical experiments with the p.Leu230Pro altered XPF because we were unable to express and purify ERCC1-p. Leu230Pro-XPF as a result of its low stability and tendency to aggregate. We finally checked whether the FA-specific altered XPF proteins ectopically expressed in Ercc4-null MEFs can perform the incision step of ICL repair. Both p.Leu230Pro and p.Arg689Ser altered XPF completely restored the incision defect of Ercc4-null MEFs, as measured by the COMET assay (data not shown), but the cells remained hypersensitive to ICLs (Fig. 1F) . Although additional biochemical experiments are required, our results suggest that the ICL sensitivity of individuals FA104 and 1333 is not directly linked to the absence of XPF nuclease activity. It seems unlikely that the defect is a downstream step of homologous recombination because FA104 and 1333 cells are not sensitive to PARP inhibitors and are normal in Rad51 focus formation. Given that the nuclease activity of the FA-specific p.Arg689Ser altered XPF is grossly abnormal, it is tempting to speculate that the ICL-unhooking step in these FA cells leaves an intermediate aberrant substrate that is irreparable by subsequent ICLrepair factors.
Our genetic, biochemical, and functional studies, along with the characterization Table 2 ). Most of the presently known XP-F individuals suffer from a relatively mild form of XP
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. Cells from these individuals have a reduced level of XPF in the nucleus because the altered XPF has a tendency to aggregate in the cytoplasm 11 . This reduced level of nuclear XPF is insufficient to mediate complete NER, but it still has enough ICL-repair-specific functions to prevent chromosome fragility, cell-cycle arrest, and subsequent FA clinical manifestations. A second set of ERCC4 mutations, characterized in this study, allow localization of the protein to the nucleus, where they exert a certain level of NER activity but are fully deficient in ICL repair. p.Arg689Ser XPF is a stable and NER-proficient protein with an active site structure that prevents it from properly processing ICL-repair intermediates. The 30 Cy5-labeled substrate was incubated with recombinant ERCC1-XPF in the presence of 2 mM MgCl2 or 0.4 mM MnCl2, and the products were analyzed by denaturing PAGE. The incision reaction was performed essentially as described earlier 5, 11 . p.Leu230Pro XPF is more similar to the products of previously described ERCC4 mutations in that it is less stable and might have a tendency to aggregate in the cytoplasm. However, sufficient amounts of the protein are properly folded and reach chromatin, where it appears to have some activity in the removal of 6-4 PPs. Residual NER activity in the skin tissue of individual 1333 in vivo might explain why this individual has no clinically relevant skin photosensitivity, although we cannot exclude that dermatological problems will arise later in life. A final category of ERCC4 mutations is associated with XFE progeroid syndrome, which is characterized by very low levels of nuclear XPF, apparently insufficient to support either NER or ICL repair. Importantly, the only XFE-affected individual described suffered from both skin photosensitivity and anemia 9, 16 and shared some cellular features with XP (NER defect and UV-light sensitivity) and FA (extreme ICL sensitivity, DEBinduced chromosome fragility, and MMC-induced cell-cycle arrest), suggesting that XFE syndrome is characterized by a combination of XP and FA manifestations (Supplementary Table 2 ). Exhaustion of hematopoietic stem cells is also an attribute of ERCC1-XPF hypomorphic mice that mimic XFE (Laura Niedernhofer, personal communication). Microsomy, microcephaly, and liver fibrosis were likewise observed in FA individual 1333, in Ercc1-and Ercc4-deficient mice, and in the unique ERCC1-deficient individual, who all lack ICL-repair functions [17] [18] [19] [20] [21] . In a broader sense, this study demonstrates that depending on the type of ERCC4 mutation and the balance between NER and ICL-repair activities, affected individuals present with one of three clinically distinct disorders. This resembles the case of XPD, which is involved in XP complementation group D, trichothiodystrophy (MIM 601675), or Cockayne syndrome (MIM 216400) depending on the type of mutation 22 , and highlights the value of characterizing rare genetic disorders for gaining insight into the mechanisms of genome maintenance and human disease. XPF has a central role in preventing genome instability, cancer, BMF, developmental abnormalities, and premature aging. Like those of other breast and ovarian cancer susceptibility genes mutated in FA 23, 24 , the product of ERCC4 also acts downstream of FANCD2 monoubiquitination. Therefore, it is important to study FANCQ as a candidate gene in hereditary breast and ovarian cancer. show an abundance and a distribution of XPF between the cytoplasmic, nuclear and chromatin compartments comparable to a normal control, whereas 1333 reveals reduced abundance and two species of that protein with sizes predicted by its mutations but, of note, XPF is still detected in the nucleus and on chromatin with grossly unaffected ratios to the cytoplasmic fraction. Specificity of the separation of extracts from lymphoblasts is confirmed by the compartment-specific marker proteins tubulin, p300 and histone H3. Subcellular Protein Fractionation Kit from Pierce (Thermo Scientific) following the manufacturer's instructions. ) through a polycarbonate filter with 5 μm pores, incubated for 0.5 h, fixed and stained with antibodies to (6-4)PP and antibodies to HA. Data represent the average of at least 3 independent experiments ± the SD. For each experiment 100 cells were counted. (C) Normal SLX4 interactions in XPF-deficient FA individuals. SLX4 was immunoprecipitated with a polyclonal antibody raised against the first 300 amino acids of SLX4 (SLX4 N-terminus; gift from J. Rouse, Dundee). Precipitated proteins were visualized by immunoblotting with antibodies to SLX4 N-terminus, XPF, ERCC1 and MUS81. Reduced XPF and ERCC1 protein expression was found in lymphoblasts of individual 1333. In these cells, full-length and truncated XPF and MUS81 were coprecipitated with SLX4, whereas ERCC1 is barely detectable. In lymphoblasts of individual FA104, the interaction between SLX4 and its binding partners XPF-ERCC1 and MUS81 is normal. Wild type lymphoblasts (HSC93) and lymphoblasts of FA-P individuals (EUFA1354-L and 457/3) were used as controls. (D) Normal ERCC1-XPF interactions in FA104 and 1333 lymphoblast cell lines. ERCC1 was immunoprecipitated with a polyclonal antibody against ERCC1 and the precipitated proteins were visualized by immunoblotting with antibodies against XPF and P84 as internal control. Further technical details on co-immunoprecipitation conditions and antibodies used can be obtained upon request.
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column contains one of the following values: SS=splice site, NSC=non-synonymous coding, FC=frameshift coding, NFC=non-frameshift coding; AA change: amino acid change in the affected protein; GN: Gene name; NRR: Number of non-redundant reads; SNV Q: the phred-scaled likelihood that the genotype is identical to the reference; GT Q: Phred-scaled likelihood that the genotype is wrong. 
